Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting
News Oct 30, 2009
The poster presentation, entitled “A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung” will be delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita’s team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
RELATED ARTICLES
Research Team Discovers Compound that Stops Cancer From Spreading
NewsUsing a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.
READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs
NewsPhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.
READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation Agreement
NewsSiemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Login
You must be logged in to post a comment.